Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Semaglutide controlled release - Mapi Pharma

Next Previous
Drug Profile

Semaglutide controlled release - Mapi Pharma

Alternative Names: GLP-1 - Mapi Pharma; GLP-1 Depot; Semaglutide - Mapi Pharma

Latest Information Update: 01 Sep 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Mapi Pharma
  • Class Antidementias; Antihyperglycaemics; Cardiovascular therapies; Glucagon-like peptides; Hepatoprotectants; Obesity therapies; Urologics; Vascular disorder therapies
  • Mechanism of Action Glucagon-like peptide-1 receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Diabetes mellitus

Most Recent Events

  • 09 Aug 2026 Phase-I/II clinical trials in Diabetes mellitus (Treatment-experienced) in Israel (SC) (NCT07563699)
  • 01 Jun 2026 Mapi Pharma plans a phase I/II trial for Diabetes mellitus (SC) in June 2026 (NCT07563699)
  • 19 Oct 2022 Phase-II clinical trials in Diabetes mellitus in Israel (Parenteral) (Mapi Pharma pipeline, October 2022)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top